Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
@article{Chappell2016IsFB,
title={Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?},
author={Nicole P. Chappell and Caela R. Miller and Aaron D Fielden and Jason C. Barnett},
journal={Journal of oncology practice},
year={2016},
volume={12 7},
pages={
e775-83
}
}PURPOSE
Although the Food and Drug Administration has approved incorporation of bevacizumab (BEV) into the treatment of platinum-resistant ovarian cancer (PROC), cost-value measures are an essential consideration, as evidenced by the recent ASCO Value Framework initiative. We assessed the cost-effectiveness and reviewed the net health benefit (NHB) of this expensive treatment.
METHODS
A cost-effectiveness decision model was constructed using results from a phase III trial comparing BEV plus… CONTINUE READING